Faculty Opinions recommendation of Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718458515.793501282 ◽

2014 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Adult Patients ◽

Multicenter Clinical Trial ◽

Japanese Adult ◽

Safety And Efficacy ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial

The Journal of Dermatology ◽

10.1111/1346-8138.12534 ◽

2014 ◽

Vol 41 (7) ◽

pp. 577-585 ◽

Cited By ~ 42

Author(s):

Masutaka Furue ◽

Yasumi Kitahara ◽

Hideto Akama ◽

Seiichiro Hojo ◽

Nobukazu Hayashi ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Adult Patients ◽

Multicenter Clinical Trial ◽

Japanese Adult ◽

Safety And Efficacy ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor

10.1542/peds.141.1_meetingabstract.275 ◽

2018 ◽

Author(s):

Amy S. Paller ◽

Wynnis L. Tom ◽

Mark G. Lebwohl ◽

Mark Boguniewicz ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.337 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB86 ◽

Cited By ~ 1

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Two Phase ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

The Journal of Dermatology ◽

10.1111/1346-8138.15173 ◽

2019 ◽

Vol 47 (2) ◽

pp. 114-120 ◽

Cited By ~ 8

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Ryusei Murata ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Adult Patients ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

P7 3: SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE‐TO‐SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)

Internal Medicine Journal ◽

10.1111/imj.23_15529 ◽

2021 ◽

Vol 51 (S4) ◽

pp. 25-25

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Severe Atopic Dermatitis ◽

Safety And Efficacy

Download Full-text

A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

10.1542/peds.141.1_meetingabstract.251 ◽

2018 ◽

Author(s):

Adelaide A. Hebert ◽

Lawrence F. Eichenfield ◽

Mark G. Lebwohl ◽

Amy S. Paller ◽

Eric L. Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.04.054 ◽

2016 ◽

Vol 75 (3) ◽

pp. 506-515 ◽

Cited By ~ 84

Author(s):

Eric L. Simpson ◽

Abhijit Gadkari ◽

Margitta Worm ◽

Weily Soong ◽

Andrew Blauvelt ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Adult Patients ◽

Controlled Clinical Trial ◽

Severe Atopic Dermatitis ◽

Meaningful Improvement ◽

Patient Reported

Download Full-text

One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.05.102 ◽

2020 ◽

Cited By ~ 1

Author(s):

Hideaki Uchida ◽

Masahiro Kamata ◽

Aika Kato ◽

Itsumi Mizukawa ◽

Ayu Watanabe ◽

...

Keyword(s):

Atopic Dermatitis ◽

Retrospective Study ◽

Real World ◽

Clinical Effectiveness ◽

Adult Patients ◽

Laboratory Safety ◽

Single Center ◽

Japanese Adult ◽

One Year

Download Full-text

Application of phosphodiesterase 4 inhibitor for atopic dermatitis

Folia Pharmacologica Japonica ◽

10.1254/fpj.144.154 ◽

2014 ◽

Vol 144 (4) ◽

pp. 154-159

Author(s):

Naoto Ishii ◽

Hisatsugu Wakita ◽

Kazuki Miyazaki ◽

Yasutaka Takase ◽

Osamu Asano ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: A phase 1b clinical trial

The Journal of Dermatology ◽

10.1111/1346-8138.16179 ◽

2021 ◽

Author(s):

Risa Konishi ◽

Ryota Tanaka ◽

Sae Inoue ◽

Yuki Ichimura ◽

Toshifumi Nomura ◽

...

Keyword(s):

Clinical Trial ◽

Phosphodiesterase 4 ◽

Phase 1B ◽

Phosphodiesterase 4 Inhibitor

Download Full-text